G protein-coupled receptor (GPCR) signaling represents one of the most fundamental and evolutionarily conserved transmembrane signaling in eukaryotic cells[@gpcr]. GPCRs constitute the largest superfamily of membrane receptors in the human genome, with approximately 800 members encoded by roughly 3% of the protein-coding genome[@human]. These receptors are targets for approximately 30-40% of all modern therapeutic agents, making them the single most important class of drug targets in medicine[@gpcra]. In the nervous system, GPCRs mediate signaling by virtually every known neurotransmitter and neuromodulator, including dopamine, serotonin, glutamate, GABA, acetylcholine, and numerous neuropeptides.
The significance of GPCR signaling in neurodegenerative cannot be overstated. Dopamine receptors, which are GPCRs, are central to Parkinson's disease pathophysiology and treatment[@dopamine]. Similarly, muscarinic acetylcholine receptors represent important therapeutic targets in Alzheimer's disease and schizophrenia. The metabotropic glutamate receptors modulate excitotoxicity and synaptic plasticity, offering potential neuroprotective strategies[@mglurs]. Understanding GPCR signaling provides essential foundation for developing novel therapeutics for neurodegenerative disorders.
All GPCRs share a common seven-transmembrane domain architecture, consisting of seven hydrophobic alpha-helices that span the lipid bilayer[@gpcrc]. This distinctive structure creates an extracellular ligand-binding domain and an intracellular domain that couples to G [@seven]. The transmembrane helices are connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3), with the C-terminus located intracellularly and the N-terminus extracellularly[@gpcrd].
The ligand-binding pocket varies considerably among different GPCR subfamilies, reflecting the diverse nature of their endogenous ligands[@ligandbinding]. Class A (rhodopsin-like) receptors typically bind small molecules and peptides in a pocket formed by the transmembrane helices[@class]. Class B (secretin-like) receptors have larger N-terminal domains that engage peptide ligands[@classa]. The structural diversity of GPCRs enables their responsiveness to photons, odorants, tastants, hormones, neurotransmitters, and even mechanical stimuli[@gpcre].
GPCRs are classified into six major families based on sequence homology and functional similarity[@gpcrf]. The GRAFS classification system divides GPCRs into Glutamate, Rhodopsin, Adhesion, Frizzled, and Secretin families[@grafs]. The Class A (Rhodopsin) family is the largest, comprising approximately 85% of all human GPCRs and including receptors for small molecules like dopamine, serotonin, and adrenaline[@rhodopsin].
Within the rhodopsin family, receptors are further divided into subfamilies based on ligand type and phylogenetic relationships[@rhodopsina]. The amine subfamily includes receptors for dopamine, serotonin, norepinephrine, acetylcholine, and histamine[@amine]. The peptide receptor subfamily encompasses receptors for opioids, tachykinins, and numerous other neuropeptides[@peptide]. The rhodopsin family also includes receptors for prostaglandins, adenosine, and cannabinoid molecules[@prostanoid].
The canonical GPCR signaling pathway involves activation of heterotrimeric G consisting of alpha, beta, and gamma subunits[@heterotrimeric]. In the inactive state, the Gα subunit binds GDP and forms a complex with Gβγ[@protein]. Upon ligand binding, the GPCR undergoes a conformational change that allows it to act as a guanine nucleotide exchange factor (GEF) for the Gα subunit[@gpcrg].
The activated GPCR catalyzes exchange of GDP for GTP on the Gα subunit, causing dissociation of the Gα-GTP complex from Gβγ[@gtp]. Both Gα-GTP and free Gβγ can then regulate downstream effector enzymes and ion channels[@proteina]. The signal is terminated by the intrinsic GTPase activity of Gα, which hydrolyzes GTP to GDP, allowing re-association with Gβγ[@gtpa]. Regulators of G protein signaling (RGS ) accelerate GTP hydrolysis, providing rapid signal termination[@rgs].
Heterotrimeric G are divided into four main families based on the Gα subunit[@proteinb]:
Gs family: Gαs stimulates adenylate cyclase, increasing intracellular cAMP levels[@signaling]. Receptors coupled to Gs include β-adrenergic receptors and dopamine D1 receptors[@gscoupled].
Gi/o family: Gαi inhibits adenylate cyclase, reducing cAMP production[@signalinga]. This family also includes Gαo, the most abundant Gα in the brain[@brain]. Gi-coupled receptors include dopamine D2/D3 receptors, opioid receptors, and muscarinic M2/M4 receptors[@gicoupled]. Gi/o activation also opens G protein-gated inward rectifier potassium (GIRK) channels, hyperpolarizing neurons[@girk].
Gq/11 family: Gαq activates phospholipase C-beta (PLCβ), leading to generation of inositol trisphosphate (IP3) and diacylglycerol (DAG)[@signalingb]. This pathway mobilizes intracellular calcium and activates protein kinase C[@plc]. Gq-coupled receptors include muscarinic M1/M3 receptors and metabotropic glutamate group I receptors[@gqcoupled].
G12/13 family: Gα12/13 regulates Rho GTPase signaling through interaction with RhoGEFs[@signalingc]. This pathway controls cytoskeletal dynamics and cell migration[@rho].
The activation of G leads to production of second messengers that propagate signals within the cell[@second]. Cyclic AMP (cAMP), produced by adenylate cyclase, activates protein kinase A (PKA) and Epac [@camp]. PKA phosphorylates numerous targets including transcription factors, ion channels, and metabolic enzymes[@pka].
The phospholipase C pathway generates IP3, which releases calcium from intracellular stores in the endoplasmic reticulum[@calcium]. DAG, together with calcium, activates conventional and novel protein kinase C isoforms[@dag]. These second messenger pathways converge on numerous downstream targets to produce diverse cellular responses[@seconda].
Beyond G protein-mediated signaling, GPCRs can signal through beta-arrestin adapter [@betaarrestin]. Upon GPCR phosphorylation by G protein-coupled receptor kinases (GRKs), beta-arrestins bind to the receptor, preventing further G protein coupling and targeting the receptor for internalization[@grks]. However, beta-arrestin-bound receptors can activate downstream signaling cascades including MAPK pathways[@arrestindependent].
Bias signaling refers to the ability of certain ligands to preferentially activate either G protein or beta-arrestin pathways[@biased]. Biased agonists may provide therapeutic benefits with reduced side effects by selectively engaging beneficial signaling pathways[@biaseda]. This concept has important implications for drug development targeting GPCRs in neurodegenerative [@bias].
Dopamine receptors are among the most clinically significant GPCRs in neurodegenerative disease[@dopaminea]. The D1-like family (D1, D5) couples to Gs , increasing cAMP and promoting neuronal excitation[@receptor]. The D2-like family (D2, D3, D4) couples to Gi , inhibiting cAMP production and hyperpolarizing neurons[@receptora].
In Parkinson's disease, loss of dopaminergic neurons in the substantia nigra leads to dopamine deficiency in the striatum[@dopamineb]. D1-mediated direct pathway activity decreases while D2-mediated indirect pathway activity increases, producing the characteristic motor symptoms[@basal]. Dopamine replacement therapy and dopamine agonists aim to restore dopaminergic signaling[@dopaminec].
Dysregulation of D3 receptors has been implicated in impulse control disorders associated with dopamine agonist therapy[@impulse]. The mesolimbic D3 receptors play crucial roles in reward processing and addiction[@mesolimbic]. Understanding dopamine receptor signaling continues to guide therapeutic development for PD and other movement disorders[@dopamined].
Muscarinic receptors are divided into M1-M5 subtypes, with M1, M3, and M5 coupling to Gq and M2, M4 coupling to Gi[@muscarinica]. In the brain, muscarinic receptors modulate cognition, attention, and memory[@muscarinicb]. M1 receptors are highly expressed in the cortex and hippocampus, making them attractive targets for Alzheimer's disease therapy[@hippocampus].
Muscarinic agonists have been explored as cognitive enhancers, though side effects have limited their clinical utility[@muscarinicc]. The M1/M4 agonist xanomeline showed promise in clinical trials for Alzheimer's disease but was discontinued due to peripheral side effects[@xanomeline]. Novel approaches including M1-selective allosteric modulators may provide cognitive benefits with improved tolerability[@allosteric].
Metabotropic glutamate receptors (mGluRs) are divided into three groups based on pharmacology and signaling [@mglur]. Group I mGluRs (mGlu1, mGlu5) are Gq-coupled and regulate neuronal excitability and plasticity[@group]. Group II (mGlu2, mGlu3) and Group III (mGlu4, mGlu6, mGlu7, mGlu8) are Gi-coupled and modulate neurotransmitter release[@groupa].
mGlu5 receptors have been implicated in excitotoxicity and are potential therapeutic targets for neurodegenerative [@mglu]. Negative allosteric modulators (NAMs) of mGlu5 have shown efficacy in animal models of Parkinson's disease[@mglua]. mGlu4 positive allosteric modulators (PAMs) may provide neuroprotection by reducing glutamate release[@mglub].
Adenosine A2A receptors are Gs-coupled receptors highly expressed in the striatum where they modulate dopaminergic signaling[@receptors]. A2A antagonists including istradefylline have been approved for Parkinson's disease to reduce motor symptoms[@antagonists]. The A2A receptor represents an attractive target because of its relatively restricted expression in the brain[@basala].
Cannabinoid receptors (CB1, CB2) are activated by endogenous cannabinoids and cannabis-derived compounds[@cannabinoid]. CB1 receptors are abundant in the basal ganglia and modulate motor control and reward[@basalb]. Cannabinoids have been explored for their potential neuroprotective properties in PD models[@cannabinoids]. However, psychoactive side effects and complex pharmacology have limited therapeutic development[@cannabinoida].
Serotonin receptors (5-HT) are diverse, with most being GPCRs and a few being ligand-gated ion channels[@serotonin]. The 5-HT1 family (5-HT1A, 5-HT1B, 5-HT1D) are Gi-coupled and inhibit adenylate cyclase[@receptorsa]. 5-HT2 receptors are Gq-coupled and activate phospholipase C[@receptorsb]. 5-HT4, 5-HT6, and 5-HT7 receptors are Gs-coupled and increase cAMP[@receptorsc].
Serotonergic dysfunction is implicated in depression, anxiety, and neurodegenerative disorders[@serotonina]. 5-HT1A agonists have shown neuroprotective effects in PD models[@hta]. 5-HT2A antagonists are used in schizophrenia treatment and may provide cognitive benefits[@htaa].
Traditional drug development has focused on orthosteric ligands that bind the same site as endogenous agonists[@orthosteric]. Dopamine agonists including pramipexole, ropinirole, and rotigotine are widely used in Parkinson's disease treatment[@dopaminee]. These compounds directly stimulate D2-family receptors to compensate for endogenous dopamine deficiency[@agonist].
Dopamine antagonists are essential for treating schizophrenia and other psychotic disorders[@antipsychotics]. Both typical (first-generation) and atypical (second-generation) antipsychotics primarily block D2 receptors[@blockade]. The discovery of serotonin-dopamine antagonism (5-HT2A) explained the reduced extrapyramidal side effects of atypical antipsychotics[@htab].
Allosteric modulators bind to sites distinct from the orthosteric ligand-binding pocket, offering potential advantages including greater subtype selectivity and safety[@allosterica]. Positive allosteric modulators (PAMs) enhance agonist efficacy without directly activating the receptor[@pams]. Negative allosteric modulators (NAMs) reduce agonist potency or efficacy[@allostericb].
Allosteric modulators for muscarinic receptors have shown particular promise for treating cognitive disorders[@muscarinicd]. The M1 PAM PQCA improved cognition in animal models without producing side effects associated with orthosteric agonists[@pqca]. Similar approaches are being explored for other GPCRs implicated in neurodegeneration[@gpcrh].
Biased agonists preferentially activate specific downstream signaling pathways over others[@biasedb]. This concept offers the potential to separate therapeutic benefits from side effects by selectively engaging beneficial signaling cascades[@functional]. Carvacrol has been identified as a biased agonist for the dopamine D2 receptor that may provide anti-parkinsonian effects with reduced dyskinesia liability[@carvacrol].
The development of biased ligands requires careful characterization of signaling pathways and their behavioral correlates[@biasa]. This approach represents a frontier in GPCR drug discovery with implications for multiple neurological disorders[@biasedc].
Prolonged GPCR activation leads to desensitization through multiple including receptor phosphorylation, beta-arrestin binding, and internalization[@receptorb]. G protein-coupled receptor kinases (GRKs) phosphorylate activated receptors, creating docking sites for beta-arrestins[@grk]. Beta-arrestin binding prevents further G protein coupling and targets receptors for clathrin-mediated endocytosis[@betaarrestina].
Internalized receptors can be recycled back to the plasma membrane or targeted for lysosomal degradation[@receptorc]. The balance between recycling and degradation determines receptor density and signaling capacity[@receptord]. Understanding these processes informs dosing strategies and predicts side effects of chronic drug treatment[@chronic].
The subcellular localization of GPCRs is tightly regulated and critically affects their signaling functions[@gpcri]. Dopamine D1 receptors are primarily localized to dendritic spines in striatal medium spiny neurons[@receptore]. D2 receptors are found on both presynaptic terminals and postsynaptic dendrites[@receptorf]. This differential localization determines the circuits modulated by dopaminergic signaling[@dopaminef].
Axonal targeting of GPCRs involves specific trafficking signals and interaction with scaffolding [@axonal]. The PDZ domain-containing spinophilin and neurabin organize GPCR signaling complexes[@scaffolding]. Disruption of GPCR trafficking contributes to neuronal dysfunction in disease states[@trafficking].
GPCRs localize to specialized membrane microdomains called lipid rafts that are enriched in cholesterol and sphingolipids[@lipid]. The localization of GPCRs to lipid rafts affects their coupling efficiency and signaling specificity[@raft]. Disruption of lipid raft integrity has been implicated in neurodegenerative processes[@rafts].
Single-cell transcriptomics has revealed unexpected heterogeneity in GPCR expression across neuronal populations[@gpcrj]. These findings may enable more precise targeting of specific neuronal subtypes[@neuronal]. Cryo-electron microscopy has revolutionized structural studies of GPCRs, enabling visualization of active conformations and ligand-binding sites[@gpcrk].
Optogenetic and chemogenetic approaches allow selective manipulation of GPCR signaling in specific circuits[@optogenetics]. Designer receptors exclusively activated by designer drugs (DREADDs) based on muscarinic receptors enable chemogenetic control of neuronal activity[@dreadds]. These tools are accelerating understanding of GPCR function in neural circuits relevant to neurodegenerative [@chemogenetics].
Astrocytes express numerous GPCRs that regulate their functions in neural circuit homeostasis[@astrocyte]. Astrocytic Gq-coupled receptors including mGlu5 and P2Y1 receptors mobilize calcium waves that propagate across astrocyte networks[@calciuma]. These calcium signals regulate glutamate uptake, potassium buffering, and release of gliotransmitters.
Astrocyte GPCR dysfunction contributes to neuroinflammation in neurodegenerative [@astrocytes]. Reactive astrocytes upregulate certain GPCRs while downregulating others, altering their responses to neural activity[@reactive]. Understanding astrocyte GPCR signaling may reveal novel therapeutic targets for neuroprotection.
Microglia, the resident immune cells of the brain, express diverse GPCRs that regulate their activation states[@microglial]. Chemokine receptors including CX3CR1 modulate microglial surveillance and inflammatory responses[@cxcr]. P2X and P2Y nucleotide receptors regulate microglial phagocytosis and cytokine release[@receptorsd].
Microglial GPCR signaling is implicated in neuroinflammation surrounding amyloid plaques and Lewy bodies[@microglia]. Modulating microglial GPCRs may provide approaches to reduce harmful inflammation while preserving protective immune functions[@microgliala].
Multiple GPCR systems are affected in Alzheimer's disease including cholinergic, serotonergic, and glutamatergic signaling[@gpcrs]. Loss of muscarinic M1 receptors in AD brain correlates with cognitive decline[@loss]. 5-HT4 and 5-HT6 receptor expression changes may contribute to memory deficits[@changes].
Targeting GPCRs in AD includes muscarinic agonists, serotonin receptor modulators, and metabotropic glutamate ligands[@gpcrl]. Clinical trials have shown mixed results, highlighting the complexity of GPCR dysfunction in AD[@clinical].
GPCR dysregulation in Parkinson's disease extends beyond dopamine receptors to affect adenosine, cannabinoid, and serotonin systems[@gpcrsa]. Upregulation of adenosine A2A receptors in the parkinsonian striatum enhances motor inhibition[@upregulation]. CB1 receptor changes alter basal ganglia output and may contribute to dyskinesias[@dyskinesias].
GPCRs expressed in motor neurons and glial cells are implicated in ALS pathogenesis[@gpcrsb]. Group I metabotropic glutamate receptors may contribute to excitotoxicity in ALS[@mglura]. Modulating GPCRs represents a therapeutic strategy under investigation[@als].
GPCRs can form dimers and higher-order oligomers that affect their pharmacology and signaling[@gpcrm]. Dopamine D2 receptors form heteromers with adenosine A2A receptors that have distinct signaling properties[@daa]. These interactions represent potential drug targets[@heteromer].
Advances in single-cell proteomics will reveal cell-type-specific GPCR expression patterns[@singlecell]. These approaches may identify novel therapeutic targets and [@gpcrn].
Engineered GPCRs and DREADDs enable precise manipulation of neural circuits[@synthetic]. These tools have applications in basic research and potential therapeutic development[@dreadd].